GHRP-6 · Research brief

GHRP-6 Acetate Ghrelin Receptor Agonism — Peptide Insights

Real Peptides Research TeamEditorial

Updated March 30, 202611 min read

54 WORDS

Short answer

Growth hormone releasing peptides aren't all created equal. Some work through hypothalamic pathways, others through pituitary stimulation. But GHRP-6 acetate ghrelin receptor agonism operates through a mechanism most researchers initially overlooked. It binds to the same receptor responsible for signaling hunger and metabolic stress, triggering a cascade that extends far beyond simple GH elevation.

Key takeaways

GHRP-6 acetate binds GHS-R1a (ghrelin receptors) in the hypothalamus and pituitary with nanomolar affinity, mimicking endogenous ghrelin to trigger pulsatile GH release within 15–30 minutes of administration.
GHRP-6 acetate ghrelin receptor agonism activates the same hunger and metabolic signaling pathways as natural ghrelin, increasing appetite and altering energy expenditure. Effects absent in GHRH analogues like Sermorelin or CJC-1295.
Typical research dosing ranges from 1–6 mcg/kg body weight via subcutaneous injection, with a plasma half-life of 20–30 minutes but downstream GH effects lasting 90–120 minutes.
Unlike continuous ghrelin receptor agonists like MK-677, GHRP-6 produces acute pulsatile GH spikes that more closely mimic natural secretion patterns, reducing the risk of receptor desensitization in chronic studies.
GHRP-6 shows higher selectivity than Hexarelin (less cortisol elevation) but broader metabolic effects than Ipamorelin (stronger appetite stimulation), making it ideal for research requiring both GH and metabolic signaling.
Lyophilized GHRP-6 acetate requires reconstitution with bacteriostatic water and storage at 2–8°C after mixing, with stability maintained for 28 days under proper refrigeration.
Research applications include growth hormone physiology, metabolic regulation during caloric deficit, neurogenesis studies, and appetite/eating behavior models. Areas where ghrelin receptor activation is a key variable.

We've supplied research-grade GHRP-6 to laboratories studying this exact mechanism for years. The gap between theoretical peptide function and actual receptor-level activity is where most protocols fail. And where understanding ghrelin receptor agonism becomes essential.

What is GHRP-6 acetate ghrelin receptor agonism and how does it work?

GHRP-6 acetate ghrelin receptor agonism is the binding of the synthetic hexapeptide GHRP-6 to ghrelin receptors (GHS-R1a) in the hypothalamus and pituitary, mimicking the action of endogenous ghrelin to trigger growth hormone secretion. Unlike direct GH administration, this mechanism stimulates the body's natural pulsatile release pattern while simultaneously signaling metabolic hunger pathways. Creating a dual effect on both anabolic signaling and energy homeostasis that other growth hormone secretagogues don't replicate.

Yes, GHRP-6 acetate functions as a ghrelin receptor agonist. But calling it a simple GH secretagogue misses the broader metabolic picture. The ghrelin receptor (also called the growth hormone secretagogue receptor type 1a, or GHS-R1a) exists primarily in the arcuate nucleus of the hypothalamus and the anterior pituitary. When GHRP-6 binds to this receptor, it doesn't just trigger growth hormone release. It activates the same neural circuits that drive appetite, energy expenditure, and fat utilization during caloric restriction. This article covers the specific mechanism of GHRP-6 acetate ghrelin receptor agonism, how it differs from other peptide secretagogues, and what current research reveals about receptor selectivity, dosing response curves, and applications in metabolic and anabolic research models.

The Ghrelin Receptor System and GHRP-6 Binding Mechanism

Ghrelin is an endogenous peptide hormone secreted primarily by enteroendocrine cells in the gastric fundus when the stomach is empty. It circulates to the hypothalamus, where it binds to GHS-R1a receptors and signals the brain that energy stores are depleted. Triggering hunger, reducing energy expenditure, and promoting fat storage. This is the body's natural response to fasting or caloric deficit. GHRP-6 acetate, a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, mimics ghrelin's structure closely enough to bind the same receptor with high affinity. But without requiring the acylation (fatty acid modification) that endogenous ghrelin needs for full activity.

The binding affinity of GHRP-6 to GHS-R1a has been measured in the low nanomolar range (Ki approximately 2–10 nM depending on assay conditions), making it one of the most potent synthetic ghrelin mimetics studied. Once bound, GHRP-6 activates intracellular signaling cascades including phospholipase C (PLC), increased intracellular calcium mobilization, and activation of protein kinase C (PKC) pathways. The same downstream signals triggered by natural ghrelin. In the pituitary somatotrophs (growth hormone-secreting cells), this cascade leads to rapid release of stored GH within 15–30 minutes of administration, followed by a secondary wave of synthesis and release over the next 2–3 hours.

What makes GHRP-6 acetate ghrelin receptor agonism unique is its selectivity. Other growth hormone releasing peptides like GHRP-2 or Hexarelin also bind GHS-R1a, but GHRP-6 shows less cross-reactivity with other receptor families. Specifically, it has minimal cortisol or prolactin elevation compared to GHRP-2, which acts on additional pathways. The acetate salt form (GHRP-6 acetate) refers to the counterion used during synthesis and lyophilization. Acetic acid stabilizes the peptide in powder form and maintains pH during reconstitution, but the active molecule remains the same hexapeptide sequence. Research from the Journal of Endocrinology demonstrated that GHRP-6 administration at 1 mcg/kg body weight in animal models produced peak GH levels 5–8 times baseline within 20 minutes, with effects sustained for up to 90 minutes post-injection.

GHRP-6 Acetate Ghrelin Receptor Agonism vs Other GH Secretagogues

Not all growth hormone releasing peptides work through the same mechanism, and not all ghrelin receptor agonists produce the same effects. GHRP-6 acetate ghrelin receptor agonism differs from compounds like Sermorelin, CJC-1295, and Ipamorelin in receptor target, signaling pathway, and secondary metabolic effects. Sermorelin (also called GRF 1-29) is a growth hormone releasing hormone (GHRH) analogue. It binds to GHRH receptors in the pituitary, not ghrelin receptors. This means sermorelin stimulates GH release through a completely different mechanism, with no direct effect on hunger signaling or metabolic regulation. Sermorelin's effects are also more dependent on endogenous GHRH tone and somatostatin inhibition, making it less consistent in older research models where GHRH receptor density has declined.

CJC-1295 is a modified GHRH analogue with an extended half-life (4–8 days depending on formulation) due to binding with serum albumin. Like sermorelin, it acts on GHRH receptors, not ghrelin receptors. So it lacks the appetite and metabolic signaling effects that define GHRP-6 acetate ghrelin receptor agonism. Ipamorelin is closer to GHRP-6 in that it also binds GHS-R1a, but it is a more selective agonist with virtually no effect on cortisol, prolactin, or appetite. Making it a "cleaner" GH secretagogue but one that misses the broader metabolic effects researchers sometimes seek. GHRP-6, in contrast, does increase appetite in most models (an effect mediated by hypothalamic ghrelin receptor activation), which can be a confounding variable in metabolic studies but is also a key feature when studying energy balance and nutrient partitioning.

MK-677 (ibutamoren) is an oral ghrelin receptor agonist that also binds GHS-R1a, but unlike GHRP-6, it has a half-life of 24 hours and produces sustained GH and IGF-1 elevation rather than the pulsatile pattern seen with injectable peptides. This makes MK-677 useful for chronic dosing studies, but the continuous receptor activation can lead to desensitization over time. A phenomenon less pronounced with intermittent GHRP-6 acetate ghrelin receptor agonism. Research published in the Journal of Clinical Endocrinology & Metabolism found that MK-677 at 25 mg daily increased mean 24-hour GH concentration by 97% and IGF-1 by 60% in healthy adults, but also caused mild insulin resistance and water retention. Side effects linked to continuous GHS-R1a activation. GHRP-6, administered acutely, produces sharp GH peaks without the chronic metabolic adaptations.

GHRP-6 Acetate Ghrelin Receptor Agonism: Dosing, Bioavailability, and Research Models

Dosing for GHRP-6 acetate ghrelin receptor agonism in research models typically ranges from 1 mcg/kg to 6 mcg/kg body weight per injection, delivered via subcutaneous or intravenous routes. The peptide is not orally bioavailable due to rapid degradation by gastric and pancreatic proteases. Like most small peptides, it requires injection to reach systemic circulation intact. Peak plasma concentrations occur within 10–20 minutes of subcutaneous administration, with a half-life of approximately 20–30 minutes. Despite this short half-life, the downstream effects on GH secretion last 90–120 minutes, reflecting the time required for GH synthesis and release from pituitary stores.

Reconstitution of lyophilized GHRP-6 acetate is performed using bacteriostatic water (0.9% benzyl alcohol) to allow multi-dose use over 28 days when stored at 2–8°C. Standard reconstitution dilutes 5 mg of peptide powder in 2 mL bacteriostatic water, yielding a concentration of 2.5 mg/mL (2,500 mcg/mL). For a 200 mcg dose in a research model, this requires 0.08 mL (80 microliters) per injection. Dosing frequency in acute studies is typically 2–3 times daily to maintain pulsatile GH elevation, though chronic protocols sometimes reduce to once daily to avoid receptor desensitization. Storage before reconstitution should be at −20°C to preserve peptide integrity. Lyophilized GHRP-6 acetate is stable for 18–24 months under these conditions.

Research applications of GHRP-6 acetate ghrelin receptor agonism include studies of growth hormone physiology, metabolic regulation during energy deficit, muscle protein synthesis in cachexia models, and neurogenesis in hippocampal tissue. A study published in Endocrinology found that GHRP-6 administration increased markers of neurogenesis (BrdU incorporation, doublecortin expression) in the dentate gyrus of adult mice, an effect mediated by both GH-dependent IGF-1 signaling and direct GHS-R1a activation in neural tissue. Another line of research examines GHRP-6's effects on gastric motility and appetite regulation. Ghrelin receptor agonism increases gastric emptying rate and food intake in rodent models, making it a tool for studying eating behavior and energy homeostasis. These secondary effects distinguish GHRP-6 acetate ghrelin receptor agonism from peptides like Tesamorelin, which target GHRH receptors and lack direct metabolic signaling.

GHRP-6 Acetate Ghrelin Receptor Agonism: Comparison

Understanding how GHRP-6 acetate ghrelin receptor agonism compares to other growth hormone secretagogues clarifies when each compound is appropriate for specific research applications.

Compound	Receptor Target	GH Release Pattern	Appetite Effect	Half-Life	Key Differentiator	Professional Assessment
GHRP-6 Acetate	GHS-R1a (ghrelin receptor)	Pulsatile, peaks at 20 min	Strong increase	20–30 min	Full ghrelin receptor agonism with metabolic signaling	Best choice for studies requiring both GH release and appetite/metabolic effects. Mimics natural fasting response
Ipamorelin	GHS-R1a (selective)	Pulsatile, peaks at 30 min	Minimal to none	2 hours	Highly selective GHS-R1a agonist, no cortisol/prolactin elevation	Preferred when isolating GH effects without appetite confounds. Cleanest secretagogue profile
Sermorelin	GHRH receptor	Pulsatile, dependent on endogenous tone	None	10–20 min	Mimics natural GHRH, not ghrelin pathway	Limited by somatostatin inhibition and GHRH receptor density. Less consistent in aged models
CJC-1295 No DAC	GHRH receptor	Pulsatile, extended duration	None	6–8 days	Long-acting GHRH analogue, albumin binding	Useful for chronic GH elevation studies without daily dosing. No ghrelin receptor activity
MK-677 (Ibutamoren)	GHS-R1a	Continuous elevation	Strong increase	24 hours	Oral bioavailability, sustained GH/IGF-1 increase	Convenient for long-term studies but risk of receptor desensitization and insulin resistance with continuous use
Hexarelin	GHS-R1a + additional pathways	Pulsatile, strongest peak	Moderate increase	30–60 min	Most potent GH secretagogue but also affects cortisol and cardiac receptors	Highest GH output but less selective. Secondary effects limit use in metabolic studies

GHRP-6 acetate ghrelin receptor agonism occupies a middle ground. Stronger appetite and metabolic effects than Ipamorelin, but more selective than Hexarelin and more consistent than Sermorelin in diverse research models. The choice depends on whether ghrelin receptor activation is a desired effect or a confounding variable.

What If: GHRP-6 Acetate Ghrelin Receptor Agonism Scenarios

What If GHRP-6 Is Administered in a Fed vs Fasted State?

Administer GHRP-6 acetate on an empty stomach. At least 2 hours after the last meal and 30 minutes before the next. GH secretion in response to GHRP-6 acetate ghrelin receptor agonism is blunted by elevated blood glucose and insulin, which suppress somatotroph responsiveness through negative feedback at the pituitary level. Studies in Growth Hormone & IGF Research show that GH release following GHRP-6 administration is reduced by 40–60% when plasma glucose exceeds 100 mg/dL compared to fasting conditions. The ghrelin receptor itself is not glucose-sensitive, but downstream GH secretion pathways are. Meaning receptor binding occurs normally, but the pituitary response is dampened.

What If GHRP-6 Is Combined with a GHRH Analogue Like CJC-1295?

Combine them. The effects are synergistic, not additive. GHRP-6 acetate ghrelin receptor agonism works through GHS-R1a, while CJC-1295 works through GHRH receptors. The two pathways converge at the somatotroph to produce GH release that exceeds either peptide alone. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that co-administration of a GHS-R1a agonist and a GHRH analogue increased GH secretion by 3–5 times compared to either compound administered individually. The mechanism is complementary: GHRP-6 amplifies GH release by reducing somatostatin (the inhibitory signal), while GHRH provides the direct secretory signal. This combination is commonly used in research models requiring maximal GH output, such as the CJC-1295 Ipamorelin stack available for similar synergistic effects.

What If Receptor Desensitization Occurs with Repeated GHRP-6 Dosing?

Rotate dosing schedules or introduce washout periods every 4–6 weeks. Continuous daily dosing of GHRP-6 acetate ghrelin receptor agonism can lead to GHS-R1a receptor downregulation, reducing GH response over time. Though this is less pronounced with GHRP-6 than with continuous agonists like MK-677. If GH output declines after 8–12 weeks of daily administration, a 7–14 day washout period allows receptor density to recover. Alternatively, cycling between different GH secretagogues (e.g., alternating GHRP-6 with Ipamorelin or Sermorelin every 4 weeks) can maintain receptor sensitivity while sustaining GH elevation across longer study timelines.

What If GHRP-6 Acetate Is Reconstituted with Sterile Water Instead of Bacteriostatic Water?

Use it within 24–48 hours and store any remaining solution at 2–8°C. Sterile water lacks the benzyl alcohol preservative found in bacteriostatic water, so bacterial contamination becomes a risk after the vial is punctured. For multi-dose use over 28 days, bacteriostatic water is required. But for single-use or same-day administration, sterile water is acceptable and may reduce injection site irritation in sensitive models. The peptide itself is equally stable in either solvent for the first 48 hours post-reconstitution.

The Mechanistic Truth About GHRP-6 Acetate Ghrelin Receptor Agonism

Here's the honest answer: GHRP-6 isn't just a GH secretagogue. It's a metabolic signal that tells the body it's starving. The ghrelin receptor didn't evolve to release growth hormone for muscle building or anti-aging. It evolved to coordinate the body's response to energy scarcity: increase hunger, preserve fat stores, mobilize glucose, and stimulate tissue repair during caloric deficit. GHRP-6 acetate ghrelin receptor agonism hijacks that system. When you administer GHRP-6, you're not just triggering GH release. You're activating the same neural circuits that drive feeding behavior, reduce energy expenditure, and shift substrate utilization toward fat oxidation.

This is why GHRP-6 increases appetite so reliably, why it affects gastric motility, and why it produces slightly different metabolic outcomes than Ipamorelin despite both binding GHS-R1a. The difference is selectivity. Ipamorelin was designed to isolate the GH-releasing function of the ghrelin receptor without triggering the hunger and metabolic pathways. It's a selective agonist. GHRP-6 is not. It activates the full receptor complex, producing the full metabolic response. That makes it more useful in research models where you want to study the interaction between GH signaling and energy homeostasis. And less useful when you want to isolate GH effects alone.

The bottom line: if your research question involves growth hormone in the context of fasting, caloric restriction, or metabolic adaptation, GHRP-6 acetate ghrelin receptor agonism is the tool that best replicates the natural physiological state. If you're studying GH effects independent of metabolic signaling, Ipamorelin or Sermorelin will give you cleaner data. The mechanism matters more than the molecule.

Our understanding of ghrelin receptor agonism continues to evolve as researchers uncover new receptor subtypes and signaling pathways. GHRP-6 remains one of the most studied peptides in this class. Not because it's the most potent, but because it activates the full physiological response that makes ghrelin receptor research relevant to metabolic disease, aging, and neurodegeneration. Real Peptides supplies research-grade GHRP-6 acetate with verified purity and exact amino acid sequencing, ensuring that the compound you're studying matches the pharmacology described in the literature. Small-batch synthesis matters when receptor binding affinity can shift with minor sequence errors. And in peptide research, consistency is everything. You can explore our full peptide collection to see how our commitment to precision extends across every compound we produce, from growth hormone secretagogues to neuropeptides like P21 and Semax.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

GHRP-6 acetate ghrelin receptor agonism stimulates the body’s endogenous growth hormone production by binding to ghrelin receptors in the hypothalamus and pituitary, triggering a natural pulsatile release pattern that mimics physiological secretion. Exogenous GH administration bypasses this system entirely, delivering synthetic hormone directly into circulation at supraphysiological levels, which suppresses endogenous GH production through negative feedback and eliminates the natural pulse pattern. GHRP-6 also activates metabolic and appetite pathways through ghrelin receptor signaling, effects that exogenous GH does not produce. Research models using GHRP-6 maintain more physiological hormone dynamics and preserve feedback regulation, while exogenous GH creates a pharmacological override of normal endocrine control.

GHRP-6 acetate ghrelin receptor agonism requires functional pituitary somatotrophs to produce GH release — if the pituitary is damaged or non-functional, GHRP-6 will bind ghrelin receptors but will not generate a GH response. This makes GHRP-6 ineffective in models of hypopituitarism or complete pituitary ablation. However, GHRP-6 may still be useful in models with partial pituitary impairment or age-related decline, as it can amplify the output of remaining functional somatotrophs. In contrast, exogenous GH or IGF-1 administration would be required in models where the pituitary cannot respond to secretagogue stimulation. Hypothalamic ghrelin receptor activation will still occur, so appetite and metabolic effects may persist even when GH secretion is blunted.

Reconstitute lyophilized GHRP-6 acetate with bacteriostatic water (0.9% benzyl alcohol) at a concentration of 2–2.5 mg/mL, gently swirling the vial without shaking to avoid peptide degradation from mechanical shear. Once reconstituted, store the solution at 2–8°C (refrigerated) and use within 28 days — bacteriostatic water preserves sterility and peptide integrity over this period. Before reconstitution, store the lyophilized powder at −20°C in a sealed container to prevent moisture absorption, where it remains stable for 18–24 months. Avoid repeated freeze-thaw cycles of the reconstituted solution, as this degrades the peptide structure and reduces receptor binding affinity. Allow the solution to reach room temperature before injection to minimize discomfort and ensure accurate dosing.

GHRP-6 produces mild elevations in cortisol and prolactin in some research models, but the effect is significantly smaller than that of GHRP-2 or Hexarelin, which have broader receptor cross-reactivity. Studies in the Journal of Endocrinology found that GHRP-6 at 1 mcg/kg increased cortisol by approximately 20–30% above baseline in rodent models, compared to 60–80% increases with GHRP-2 at equivalent doses. Prolactin elevation is minimal and transient, typically returning to baseline within 60–90 minutes post-injection. These secondary hormone effects are mediated by hypothalamic activation and stress-response pathways downstream of ghrelin receptor signaling, not by direct receptor binding in the adrenal cortex or pituitary lactotrophs. For research requiring isolated GH effects with no cortisol or prolactin elevation, Ipamorelin is the preferred alternative.

GHRP-6 acetate ghrelin receptor agonism acutely increases blood glucose and reduces insulin sensitivity in the immediate post-injection period, primarily through GH-mediated lipolysis and increased hepatic glucose output. Growth hormone is a counter-regulatory hormone that opposes insulin action, promoting gluconeogenesis and reducing peripheral glucose uptake — effects that peak 2–4 hours after GHRP-6 administration. However, chronic GHRP-6 use in research models does not consistently produce sustained insulin resistance, as the pulsatile GH pattern allows for compensatory insulin secretion and receptor recovery between doses. Studies in animal models show that continuous GH elevation (as with MK-677) produces more pronounced insulin resistance than intermittent GHRP-6 dosing. Researchers studying metabolic effects should measure fasting glucose and insulin at multiple timepoints to distinguish acute GH-mediated effects from chronic metabolic adaptation.

Yes, GHRP-6 acetate ghrelin receptor agonism has demonstrated neuroprotective and neurogenic effects in preclinical models, mediated by both direct ghrelin receptor activation in the brain and indirect IGF-1 signaling from GH release. GHS-R1a receptors are expressed in the hippocampus, hypothalamus, and cortex, where ghrelin signaling promotes synaptic plasticity, neuronal survival, and neurogenesis. A study published in Endocrinology found that GHRP-6 increased markers of adult neurogenesis in the dentate gyrus of mice, including BrdU incorporation and doublecortin expression, independent of peripheral GH elevation. Other research has shown that ghrelin receptor agonism reduces neuronal apoptosis in models of ischemic injury and oxidative stress. These effects make GHRP-6 a tool for studying the role of ghrelin signaling in cognitive function, neurodegeneration, and brain aging, separate from its growth hormone-releasing properties.

GHRP-6 acetate refers to the peptide synthesized with acetic acid as the counterion, which stabilizes the peptide during lyophilization and maintains pH during reconstitution. Other salt forms, such as GHRP-6 chloride or GHRP-6 trifluoroacetate, use different counterions but contain the same active hexapeptide sequence (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2). The salt form does not alter the mechanism of ghrelin receptor agonism or the pharmacological effects — it only affects solubility, stability, and reconstitution properties. Acetate and chloride salts are generally preferred for research use due to better solubility and lower injection site irritation compared to trifluoroacetate, which can produce acidic solutions that cause discomfort. When comparing studies or sourcing peptides, ensure that the molecular weight cited accounts for the specific salt form, as this affects accurate dosing calculations.

GHRP-6 binds GHS-R1a with similar or slightly higher affinity than acylated ghrelin (the active form of endogenous ghrelin), with Ki values in the low nanomolar range for both compounds. However, GHRP-6 has a longer duration of action because it is more resistant to enzymatic degradation — natural ghrelin is rapidly cleaved by plasma esterases and has a half-life of only 8–12 minutes, while GHRP-6 has a half-life of 20–30 minutes. GHRP-6 also does not require acylation (the octanoyl group modification) that ghrelin needs for full receptor activation, simplifying synthesis and storage. Despite these pharmacokinetic differences, GHRP-6 acetate ghrelin receptor agonism produces the same downstream signaling cascades as natural ghrelin, including GH secretion, appetite stimulation, and metabolic regulation, making it a valid tool for studying physiological ghrelin function in research settings.

Yes, somatostatin (also called somatotropin release-inhibiting factor, or SRIF) opposes GHRP-6-induced GH release by binding to somatostatin receptors on pituitary somatotrophs, reducing their responsiveness to both GHRH and ghrelin receptor signals. One advantage of GHRP-6 acetate ghrelin receptor agonism is that it partially overrides somatostatin inhibition — ghrelin receptor activation reduces somatostatin secretion from hypothalamic neurons while simultaneously amplifying the pituitary’s GH response, making GHRP-6 more effective than GHRH analogues in conditions of high somatostatin tone. Research in the Journal of Neuroendocrinology shows that GHRP-6 can restore GH secretion in aged models where elevated somatostatin is a limiting factor, whereas Sermorelin and other GHRH peptides show reduced efficacy. This is why GHRP-6 is often preferred in research models with impaired GHRH responsiveness or elevated hypothalamic somatostatin.

GHRP-6 acetate ghrelin receptor agonism is preferred in research models studying the interaction between growth hormone signaling and metabolic regulation, appetite control, or energy homeostasis — scenarios where ghrelin receptor activation is a key variable. This includes cachexia models (where appetite stimulation is desired), caloric restriction studies (where ghrelin mimetics replicate fasting physiology), and neurogenesis research (where ghrelin receptor signaling in the brain is under investigation). GHRP-6 is also useful in models where somatostatin tone is elevated or GHRH receptor density is reduced, such as aging studies, because it can override somatostatin inhibition more effectively than GHRH analogues. In contrast, Ipamorelin is preferred when isolating GH effects without appetite or metabolic confounds, and Sermorelin is used when studying GHRH pathway-specific responses. The choice depends on whether ghrelin receptor activation is a feature or a confound in the research question.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA